TY - JOUR
T1 - Continual decline in azole susceptibility rates in Candida tropicalis over a 9-year period in China
AU - Wang, Yao
AU - Fan, Xin
AU - Wang, He
AU - Kudinha, Timothy
AU - Mei, Ya Ning
AU - Ni, Fang
AU - Pan, Yu Hong
AU - Gao, Lan Mei
AU - Xu, Hui
AU - Kong, Hai Shen
AU - Yang, Qing
AU - Wang, Wei Ping
AU - Xi, Hai Yan
AU - Luo, Yan Ping
AU - Ye, Li Yan
AU - Xiao, Meng
N1 - Funding Information:
This work was supported by a Beijing Hospitals Authority Youth Programme (Grant No. QML20190301), Natural Science Foundation of China (81802042), Special Foundation for National Science and Technology Basic Research Program of China (Grant No. 2019FY101200), Beijing Nova Program (Z201100006820127), and Beijing Key Clinical Specialty for Laboratory Medicine – Excellent Project (Grant No. ZK201000).
Funding Information:
Funding. This work was supported by a Beijing Hospitals Authority Youth Programme (Grant No. QML20190301), Natural Science Foundation of China (81802042), Special Foundation for National Science and Technology Basic Research Program of China (Grant No. 2019FY101200), Beijing Nova Program (Z201100006820127), and Beijing Key Clinical Specialty for Laboratory Medicine ? Excellent Project (Grant No. ZK201000).
Publisher Copyright:
© Copyright © 2021 Wang, Fan, Wang, Kudinha, Mei, Ni, Pan, Gao, Xu, Kong, Yang, Wang, Xi, Luo, Ye, Xiao and China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study Group.
PY - 2021/7/9
Y1 - 2021/7/9
N2 - Background: There have been reports of increasing azole resistance in Candida tropicalis, especially in the Asia-Pacific region. Here we report on the epidemiology and antifungal susceptibility of C. tropicalis causing invasive candidiasis in China, from a 9-year surveillance study.
Methods: From August 2009 to July 2018, C. tropicalis isolates (n
= 3702) were collected from 87 hospitals across China. Species
identification was carried out by mass spectrometry or rDNA sequencing.
Antifungal susceptibility was determined by Clinical and Laboratory
Standards Institute disk diffusion (CHIF-NET10–14, n = 1510) or Sensititre YeastOne (CHIF-NET15–18, n = 2192) methods.
Results: Overall, 22.2% (823/3702) of the isolates were resistant to fluconazole, with 90.4% (744/823) being cross-resistant to voriconazole.
In addition, 16.9 (370/2192) and 71.7% (1572/2192) of the isolates were
of non-wild-type phenotype to itraconazole and posaconazole,
respectively. Over the 9 years of surveillance, the fluconazole
resistance rate continued to increase, rising from 5.7 (7/122) to 31.8%
(236/741), while that for voriconazole was almost the same, rising from
5.7 (7/122) to 29.1% (216/741), with no significant statistical
differences across the geographic regions. However, significant
difference in fluconazole resistance rate was noted between isolates
cultured from blood (27.2%, 489/1799) and those from non-blood (17.6%,
334/1903) specimens (P-value < 0.05), and amongst isolates
collected from medical wards (28.1%, 312/1110) versus intensive care
units (19.6%, 214/1092) and surgical wards (17.9%, 194/1086) (Bonferroni
adjusted P-value < 0.05). Although echinocandin resistance
remained low (0.8%, 18/2192) during the surveillance period, it was
observed in most administrative regions, and one-third (6/18) of these
isolates were simultaneously resistant to fluconazole.
Conclusion: The continual decrease in the rate of azole susceptibility among C. tropicalis strains has become a nationwide challenge in China,
and the emergence of multi-drug resistance could pose further threats.
These phenomena call for effective efforts in future interventions.
AB - Background: There have been reports of increasing azole resistance in Candida tropicalis, especially in the Asia-Pacific region. Here we report on the epidemiology and antifungal susceptibility of C. tropicalis causing invasive candidiasis in China, from a 9-year surveillance study.
Methods: From August 2009 to July 2018, C. tropicalis isolates (n
= 3702) were collected from 87 hospitals across China. Species
identification was carried out by mass spectrometry or rDNA sequencing.
Antifungal susceptibility was determined by Clinical and Laboratory
Standards Institute disk diffusion (CHIF-NET10–14, n = 1510) or Sensititre YeastOne (CHIF-NET15–18, n = 2192) methods.
Results: Overall, 22.2% (823/3702) of the isolates were resistant to fluconazole, with 90.4% (744/823) being cross-resistant to voriconazole.
In addition, 16.9 (370/2192) and 71.7% (1572/2192) of the isolates were
of non-wild-type phenotype to itraconazole and posaconazole,
respectively. Over the 9 years of surveillance, the fluconazole
resistance rate continued to increase, rising from 5.7 (7/122) to 31.8%
(236/741), while that for voriconazole was almost the same, rising from
5.7 (7/122) to 29.1% (216/741), with no significant statistical
differences across the geographic regions. However, significant
difference in fluconazole resistance rate was noted between isolates
cultured from blood (27.2%, 489/1799) and those from non-blood (17.6%,
334/1903) specimens (P-value < 0.05), and amongst isolates
collected from medical wards (28.1%, 312/1110) versus intensive care
units (19.6%, 214/1092) and surgical wards (17.9%, 194/1086) (Bonferroni
adjusted P-value < 0.05). Although echinocandin resistance
remained low (0.8%, 18/2192) during the surveillance period, it was
observed in most administrative regions, and one-third (6/18) of these
isolates were simultaneously resistant to fluconazole.
Conclusion: The continual decrease in the rate of azole susceptibility among C. tropicalis strains has become a nationwide challenge in China,
and the emergence of multi-drug resistance could pose further threats.
These phenomena call for effective efforts in future interventions.
KW - antifungal resistance
KW - antifungal susceptibility
KW - azole
KW - Candida tropicalis
KW - echinocandin
UR - http://www.scopus.com/inward/record.url?scp=85111135474&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111135474&partnerID=8YFLogxK
U2 - 10.3389/fmicb.2021.702839
DO - 10.3389/fmicb.2021.702839
M3 - Article
C2 - 34305872
AN - SCOPUS:85111135474
SN - 1664-302X
VL - 12
SP - 1
EP - 10
JO - Frontiers in Microbiology
JF - Frontiers in Microbiology
M1 - 702839
ER -